Detalles de la búsqueda
1.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med
; 386(9): 837-846, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235726
2.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587382
3.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med
; 383(5): 415-425, 2020 07 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32726528
4.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med
; 388(16): 1533-1534, 2023 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018470
5.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
N Engl J Med
; 386(9): 892-894, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235733
6.
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30150460
7.
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
J Infect Dis
; 216(11): 1362-1370, 2017 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029260
8.
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
Antimicrob Agents Chemother
; 61(3)2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956428
9.
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
Biologicals
; 50: 81-86, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28844541
10.
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
J Pediatric Infect Dis Soc
; 13(2): 144-147, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38219024
11.
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
J Pediatric Infect Dis Soc
; 12(8): 477-480, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466917
12.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health
; 7(3): 180-189, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634694
13.
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.
J Clin Invest
; 132(18)2022 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36106642
14.
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
Pediatr Infect Dis J
; 37(9): 886-892, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373476
15.
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
Clin Vaccine Immunol
; 24(9)2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28679495
16.
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Vaccine
; 34(25): 2847-54, 2016 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27102821
Resultados
1 -
16
de 16
1
Próxima >
>>